MicroPort CardioFlow Medtech Corporation (MROPF) Kazanmak

MicroPort CardioFlow Medtech Corp. operates as a holding company with interest in developing medical devices. The company is headquartered in Shanghai, Shanghai and currently employs 1,415 full-time employees. The company went IPO on 2021-02-04. The Company’s main business is engaged in the research and development and commercialization of transcatheter and surgical solutions for structural heart diseases. The Company’s pipelines include VitaFlow, VitaFlow Liberty (including procedural accessories as supporting supply), VitaFlow Liberty Flex, Alwide Plus, AccuSnipe, AnchorMan LAAC System and AnchorMan LAAA System, and transcatheter aortic heart valve implantation (TAVI) products, transcatheter mitral valve (TMV) products, transcatheter tricuspid valve (TTV) products, left atrial appendage (LAA) products and procedural accessories at different development stages. The firm conducts its business in the domestic and overseas markets.